<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37224800</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>A comparison of the chemiluminescence immunoassay and <i>Crithidia luciliae</i> immunofluorescence test in detecting anti-dsDNA antibodies and assessing the activity of systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>936</StartPage><EndPage>941</EndPage><MedlinePgn>936-941</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231179888</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aimed to compare the YHLO chemiluminescence immunoassay (CLIA) with the <i>Crithidia luciliae</i> immunofluorescence test (CLIFT) to detect anti-dsDNA antibodies and its correlation with disease activity in systemic lupus erythematosus (SLE).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In total, 208 patients diagnosed with SLE, 110 other autoimmune patients, 70 infectious disorders patients, and 105 healthy people were enrolled in this study. Serum samples were tested using CLIA in a YHLO chemiluminescence system and CLIFT.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall agreement between YHLO CLIA and CLIFT was 76.9% (160/208), with a moderate correlation (kappa = 0.530, <i>p</i> &lt; 0.001). The sensitivity of YHLO CLIA and CLIFT were 58.2% and 55.3%, respectively. The specificity of YHLO CLIA and CLIFT were 95.1% and 99.3%, respectively. The sensitivity of YHLO CLIA was increased to 66.8% with a specificity of 93.6% when the cut-off value was set at 24&#xa0;IU/mL. Spearman's correlation coefficient between the quantitative results of YHLO CLIA and the titers of CLIFT was 0.59 (<i>p</i> &lt; .01). A significant correlation was found between the anti-dsDNA results detected by YHLO CLIA and the SLE Disease Activity Index 2000 (SLEDAI-2K). Spearman's correlation coefficient between YHLO CLIA and SLEDAI-2K (r = 0.66, <i>p</i> &lt; .01) was higher than that of CLIFT (r = 0.60, <i>p</i> &lt; .01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Good correlation and agreement were found between YHLO CLIA and CLIFT. In addition, there was a significant correlation between YHLO CLIA and the SLE Disease Activity Index, which was superior to that of CLIFT. The YHLO chemiluminescence system is recommended for the assessment of disease activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Shiyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.</Affiliation><Identifier Source="RINGGOLD">605319</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiaoning</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.</Affiliation><Identifier Source="RINGGOLD">605319</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Limin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.</Affiliation><Identifier Source="RINGGOLD">605319</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Kongmei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.</Affiliation><Identifier Source="RINGGOLD">605319</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qitian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.</Affiliation><Identifier Source="RINGGOLD">605319</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0303-1542</Identifier><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.</Affiliation><Identifier Source="RINGGOLD">605319</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000718988">anti-dsDNA autoantibody</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003421" MajorTopicYN="Y">Crithidia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049449" MajorTopicYN="N">Luminescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Crithidia luciliae immunofluorescence test</Keyword><Keyword MajorTopicYN="N">anti-dsDNA antibodies</Keyword><Keyword MajorTopicYN="N">chemiluminescence immunoassay</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>18</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37224800</ArticleId><ArticleId IdType="doi">10.1177/09612033231179888</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>